Genetic ablation or pharmacologically-blocked cannabinoid receptor 2 (interleukin-6 regulator), as well as drug suppression of the cytokine-responsive kynurenine pathway, can both slow neurodegeneration and improve the phenotype of R6/2 HD mice (41, 42). Here, IL6 is linked to Huntington disease.